The Gauteng Health Department began a phased rollout of the Lenacapavir HIV prevention injection on Monday [1].
This initiative marks a significant shift in HIV prevention strategy by moving from daily medication to a long-acting injectable. By reducing the frequency of doses, health officials aim to increase adherence and protect high-risk populations more effectively in a region with a substantial disease burden.
The program targets approximately 56,000 high-risk individuals [3]. These patients will receive the injection twice yearly [4] to maintain protection against the virus. The rollout is part of a broader nationwide prevention initiative previously announced by the president [5].
To facilitate the distribution, the province has activated 133 participating facilities [2]. These clinics will serve as the primary hubs for administering the drug and monitoring patients as the phased approach expands.
Lenacapavir [5] represents a new tool in the public health arsenal to curb new infections. The transition to a twice-yearly schedule removes the barrier of daily pill fatigue, a common challenge in long-term HIV prevention. The Gauteng Health Department is coordinating the effort to ensure that the most vulnerable groups receive priority access to the medication [3].
Officials said the rollout is designed to address the province's high HIV burden [5]. By integrating the injection into the existing clinic infrastructure, the department intends to scale the reach of the prevention jab across the region [2].
“The program targets approximately 56,000 high-risk individuals.”
The adoption of Lenacapavir in Gauteng signifies a transition toward 'long-acting' prophylaxis. By reducing the requirement for daily adherence to just two doses per year, South Africa is attempting to close the gap between medication availability and actual usage among high-risk groups, potentially lowering the overall rate of new HIV infections in the province.
